ATE384047T1 - Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren - Google Patents
Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitorenInfo
- Publication number
- ATE384047T1 ATE384047T1 AT01965225T AT01965225T ATE384047T1 AT E384047 T1 ATE384047 T1 AT E384047T1 AT 01965225 T AT01965225 T AT 01965225T AT 01965225 T AT01965225 T AT 01965225T AT E384047 T1 ATE384047 T1 AT E384047T1
- Authority
- AT
- Austria
- Prior art keywords
- oxidosqualene
- piperidine derivatives
- cyclase inhibitors
- lanosterol cyclase
- lanosterol
- Prior art date
Links
- 108010059597 Lanosterol synthase Proteins 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00119677 | 2000-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE384047T1 true ATE384047T1 (de) | 2008-02-15 |
Family
ID=8169794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01965225T ATE384047T1 (de) | 2000-09-08 | 2001-08-29 | Piperidin-derivate zur verwendung als 2,3- oxidosqualen-lanosterol zyklase inhibitoren |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6964974B2 (de) |
| EP (1) | EP1317432B1 (de) |
| JP (1) | JP2004508354A (de) |
| KR (1) | KR20030027122A (de) |
| CN (1) | CN1231466C (de) |
| AR (1) | AR032634A1 (de) |
| AT (1) | ATE384047T1 (de) |
| AU (1) | AU2001285912A1 (de) |
| BR (1) | BR0113752A (de) |
| CA (1) | CA2419588C (de) |
| DE (1) | DE60132468T2 (de) |
| ES (1) | ES2298253T3 (de) |
| MX (1) | MXPA03002034A (de) |
| WO (1) | WO2002020483A1 (de) |
| ZA (1) | ZA200301818B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20030086A2 (en) | 2000-08-16 | 2005-02-28 | F. Hoffmann - La Roche Ag | Novel aminocyclohexane derivatives |
| BR0214967A (pt) | 2001-12-14 | 2005-05-10 | Novo Nordisk As | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente |
| US7012077B2 (en) * | 2001-12-20 | 2006-03-14 | Hoffmann-La Roche Inc. | Substituted cyclohexane derivatives |
| CA2589748C (en) * | 2004-12-24 | 2013-08-13 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
| EP2658544A4 (de) * | 2010-12-27 | 2014-05-28 | Univ Missouri | Oxidosqualenzyklase als proteintarget für antikrebs-therapeutika |
| AU2012321107A1 (en) * | 2011-10-20 | 2013-05-16 | The Curators Of The University Of Missouri | Enzyme inhibitor for cancer treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133061A (en) | 1962-11-13 | 1964-05-12 | Sterling Drug Inc | Piperidine carboxamides and derivatives thereof |
| US3914426A (en) * | 1972-11-10 | 1975-10-21 | Pfizer | Piperidinesulfonylurea derivatives for lowering blood sugar levels |
| SK94393A3 (en) | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| CA2150550A1 (en) | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
| FR2705343B1 (fr) | 1993-05-17 | 1995-07-21 | Fournier Ind & Sante | Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| GB9310066D0 (en) | 1993-05-17 | 1993-06-30 | Zeneca Ltd | Alkyl substituted heterocycles |
| TW438774B (en) | 1993-07-14 | 2001-06-07 | Hoffmann La Roche | Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines |
| MA23420A1 (fr) | 1994-01-07 | 1995-10-01 | Smithkline Beecham Corp | Antagonistes bicycliques de fibrinogene. |
| DE4407961A1 (de) | 1994-03-10 | 1995-09-14 | Thomae Gmbh Dr K | Imidazolidin-2-one, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CA2190699A1 (en) * | 1995-12-08 | 1997-06-09 | Johannes Aebi | Tertiary amines |
| DE19614204A1 (de) | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19618970A1 (de) | 1996-05-10 | 1997-11-13 | Klinge Co Chem Pharm Fab | Neue Thiazolopyridine |
| US6025372A (en) * | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| AU747531B2 (en) * | 1997-04-14 | 2002-05-16 | Millennium Pharmaceuticals, Inc. | Selective factor Xa inhibitors |
| DE19806713A1 (de) | 1998-02-18 | 1999-08-19 | Boehringer Ingelheim Pharma | Neue Urethane, ihre Thio- und Dithioanaloga, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
-
2001
- 2001-08-27 US US09/939,872 patent/US6964974B2/en not_active Expired - Fee Related
- 2001-08-29 BR BR0113752-2A patent/BR0113752A/pt not_active IP Right Cessation
- 2001-08-29 CA CA002419588A patent/CA2419588C/en not_active Expired - Fee Related
- 2001-08-29 MX MXPA03002034A patent/MXPA03002034A/es unknown
- 2001-08-29 ES ES01965225T patent/ES2298253T3/es not_active Expired - Lifetime
- 2001-08-29 AU AU2001285912A patent/AU2001285912A1/en not_active Abandoned
- 2001-08-29 EP EP01965225A patent/EP1317432B1/de not_active Expired - Lifetime
- 2001-08-29 JP JP2002525105A patent/JP2004508354A/ja active Pending
- 2001-08-29 DE DE60132468T patent/DE60132468T2/de not_active Expired - Lifetime
- 2001-08-29 WO PCT/EP2001/009941 patent/WO2002020483A1/en not_active Ceased
- 2001-08-29 AT AT01965225T patent/ATE384047T1/de not_active IP Right Cessation
- 2001-08-29 KR KR10-2003-7003436A patent/KR20030027122A/ko not_active Ceased
- 2001-08-29 CN CNB018169414A patent/CN1231466C/zh not_active Expired - Fee Related
- 2001-09-06 AR ARP010104232A patent/AR032634A1/es not_active Application Discontinuation
-
2003
- 2003-03-05 ZA ZA200301818A patent/ZA200301818B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002020483A1 (en) | 2002-03-14 |
| CN1468220A (zh) | 2004-01-14 |
| CA2419588C (en) | 2009-09-22 |
| DE60132468D1 (de) | 2008-03-06 |
| CN1231466C (zh) | 2005-12-14 |
| JP2004508354A (ja) | 2004-03-18 |
| WO2002020483A8 (en) | 2002-06-06 |
| US20020068753A1 (en) | 2002-06-06 |
| MXPA03002034A (es) | 2003-07-24 |
| EP1317432A1 (de) | 2003-06-11 |
| KR20030027122A (ko) | 2003-04-03 |
| ES2298253T3 (es) | 2008-05-16 |
| EP1317432B1 (de) | 2008-01-16 |
| AU2001285912A1 (en) | 2002-03-22 |
| BR0113752A (pt) | 2003-07-29 |
| ZA200301818B (en) | 2004-06-21 |
| CA2419588A1 (en) | 2002-03-14 |
| US6964974B2 (en) | 2005-11-15 |
| DE60132468T2 (de) | 2009-01-15 |
| AR032634A1 (es) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE437862T1 (de) | Pyrimidin-5-onderivate als ldl-pla2 inhibitoren | |
| ATE256127T1 (de) | Betacarbolinderivate als phosphodiesterase- inhibitoren | |
| DE60106252D1 (de) | Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren | |
| DE60133897D1 (de) | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren | |
| NO20026125D0 (no) | Tetrahydropyridin- eller piperidin-heterocykliske derivater | |
| ATE447553T1 (de) | Piperidinverbindungen zur verwendung als ccr-3- inhibitoren | |
| ID27838A (id) | Inhibitor 1,2,3,4-tetrahidrokinolin tersubstitusi 2-tersubstitusi 4-amino sebagai inhibitor cetp | |
| ATE446093T1 (de) | Substituierte chinazolin-derivate als aurora- kinase inhibitoren | |
| MA27230A1 (fr) | Derives d'aminoindazoles comme inhibiteurs de proteines-kinase | |
| NL300242I1 (nl) | Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers. | |
| CY2007002I1 (el) | Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης | |
| DK1534290T3 (da) | Hidtil ukendte kinasehæmmere | |
| EP1549646A4 (de) | Piperidinderivate | |
| ATE259363T1 (de) | Piperazinderivate als 5-ht1b antagonisten | |
| ATE234276T1 (de) | Diacylhydrazinderivate als integrin-inhibitoren | |
| IL162765A0 (en) | Piperidine derivatives | |
| DE60203481D1 (de) | Piperidinderivate als neurokinin 1 antagonisten | |
| IL155986A0 (en) | 4- (biphenylcarbonylamino) piperidine derivatives as mtp inhibitors | |
| IS6413A (is) | Setnir 8-arýkínólín fosfódíesterasa-4 latar | |
| ATE428420T1 (de) | Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer | |
| PL353475A1 (pl) | Pochodne 6-azauracylu hamujące interleukinę-5 | |
| ATE553097T1 (de) | Piperidin- und piperazin-substituierte n- hydroxyformamiden zur verwendung als metalloproteinaseinhibitoren | |
| ATE302781T1 (de) | Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer | |
| IL150357A0 (en) | Substituted piperazine derivatives as mtp inhibitors | |
| ATE390413T1 (de) | 4-(2-phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridinderivaten zur verwendung als serotonin-wiederaufnahmehemmer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |